A Case of Pemphigus Vulgaris in a Patient with Human Immunodeficiency Virus

Main Article Content

Charit Nayelly Chang Cruz
Alfredo Bautista de la Cruz
Estanislao Antonio Calixto

Abstract




Pemphigus vulgaris is the most common variant of autoimmune chronic blistering skin diseases. Its appearance in patients infected with acquired immunodeficiency virus (HIV) is rare. A 40-year-old woman is reported, who presented skin lesions in 90% of the body surface, characterized by blisters of 3 to 4 cm that, when broken, left denuded areas, excoriations and pruritic meliceric crusts. A skin biopsy was performed that showed a characteristic pattern of pemphigus vulgaris. Elisa for HIV positive. She evolved with septic shock and died 72 hours later. Understanding the relationship between HIV and autoimmune blistering disorders can help guide the therapeutic and prognostic management of these patients. Proposed mechanisms include molecular mimicry, polyclonal B-cell stimulation, and highly active antiretroviral therapy possibly associated with immune restoration. Clinically, these patients may present limited mucosal symptoms or develop multiple erosions that may spread, merge, and progress to exfoliative erythroderma. Glucocorticoids serve as the first line of management; however, they can have important adverse effects such as infectious complications that pose a therapeutic challenge for the doctor and could influence mortality.




Article Details

How to Cite
Chang Cruz, C. N. ., Bautista de la Cruz, A. ., & Antonio Calixto, E. (2022). A Case of Pemphigus Vulgaris in a Patient with Human Immunodeficiency Virus . International Journal of Medical Science and Clinical Research Studies, 2(12), 1479–1481. https://doi.org/10.47191/ijmscrs/v2-i12-21
Section
Articles

References

I. Didona D, Maglie R, Eming R, Hertl M, Pemphigus: Current and Future Therapeutic Strategies, Front. Immunol. 10:1418.

II. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus, Lancet 2019; 394: 882–94.

III. González RV, Fanny Cordero MCF, Domínguez CJ, Méndez FS. Pemphigus vulgaris, Med Int Méx. 2019 septiembre-octubre;35(5):708-712.

IV. Pollmann R, Schmidt T, Eming R, Hertl M. Pemphigus: A Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches, Clinical Reviews in Allergy & Immunology 2018.

V. Rehman A, Huang Y, Wan H. Evolving Mechanisms in the Pathophysiology of Pemphigus Vulgaris: A Review Emphasizing the Role of Desmoglein 3 in Regulating p53 and the Yes-Associated Protein, Life2021,11,621.

VI. Kasperkiewicz M, Ellebrecht CT, TakahashiHH, Yamagami J, Zillikens D, et al.

VII. Pemphigus, Volume 3 | Article Number 17026 | 1.

VIII. Min MS, Damstetter E, Chen AYY. Autoimmune blistering disorders in the setting of human immunodeficiency virus infection. International Journal of Women's Dermatology 4 (2018) 159–165.

IX. Medina CDE, González GR, Pérez LJA, Rodríguez PG, Herrera NMG, et al. AidS and pemphigus vulgaris: Case report. Dermatology CMQ 2013;11(3):203-207.

X. Etzioni A. Immune deficiency and autoimmunity. Autoimmune Rev 2003; 2:364– 9. Volume 2, Issue 6, October 2003, Pages 364-369.

XI. Touzeau VR, Skoll M, Tajpara P, Kienzl P, Wesinger A, et al. Prevalence of Skinspecific Autoantibodies in HIV-infected Patients and Uninfected Controls, Acta Derm Venereol 2019; 99: 978–983.

XII. Chu KY, Yu HS, Yu S. Current, and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview. J. Clin. Med. 2022, 11, 3528.

Most read articles by the same author(s)

<< < 1 2